TY - JOUR T1 - Can a better understanding of frailty improve the quality of life of patients with fibrotic interstitial lung diseases? JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02255-2019 VL - 55 IS - 1 SP - 1902255 AU - Bernard Aguilaniu Y1 - 2020/01/01 UR - http://erj.ersjournals.com/content/55/1/1902255.abstract N2 - Management of progressive fibrotic interstitial lung diseases (ILDs) has long been limited to compensatory oxygen therapy and/or corticosteroids, but work in recent years has established the efficacy of new antifibrotic treatments in slowing the decline of patients with idiopathic pulmonary fibrosis [1]. However, many factors contribute to the tolerance and efficacy of new drugs in patients with ILDs.The fate of patients with pulmonary fibrosis is also influenced by their frailty. Hence the urgent need to evaluate these patients beyond pulmonary involvement, and to consider the decline in pulmonary function as a late warning of homeostasis erosion. http://bit.ly/2LehtmU ER -